Seek Returns

EXEL vs. SNY: Exelixis vs. Sanofi Stock Comparison

How do Exelixis (EXEL) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Exelixis (EXEL) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but EXEL is classified in Biotechnology while SNY is classified in Pharmaceuticals.

Exelixis (EXEL) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Exelixis (EXEL) and Sanofi (SNY)
Profile ItemEXELSNY
NameExelixis Inc.Sanofi ADR
Country/RegionUnited StatesFrance
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization16.98 billion USD112.71 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateApril 17, 2000July 1, 2002
Security TypeCommon StockADR

Price Performance

Cumulative Growth

EXEL
SNY
GSPC
Loading price history…
Exelixis (EXEL) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Exelixis (EXEL) and Sanofi (SNY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Exelixis (EXEL) and Sanofi (SNY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Exelixis (EXEL) and Sanofi (SNY)
MetricEXELSNY
Total Return (1Y)74.98%2.73%
Total Return (3Y, Annualized)50.33%6.89%
Total Return (5Y, Annualized)31.10%3.16%

Risk Profile

Drawdown History

EXEL
SNY
GSPC
Loading price history…
Exelixis (EXEL) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Exelixis (EXEL) and Sanofi (SNY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Exelixis (EXEL) and Sanofi (SNY)
MetricEXELSNY
Volatility (1Y, Annualized)34.17%23.60%
Beta (5Y)0.410.28
Max Drawdown (5Y)-35.41%-33.52%
Avg. Volume (3M)2.33M3.29M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
EXEL and SNY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Exelixis (EXEL) and Sanofi (SNY)
MetricEXELSNY
Sharpe Ratio (1Y)2.07-0.07
Sortino Ratio (1Y)3.23-0.10

Profitability

ROE (TTM)

Exelixis (EXEL) at 44.32% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for EXEL.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max
109.18%
EXEL
44.32%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.72%

Max
109.18%
Q3
6.23%
SNY
5.72%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Exelixis (EXEL) at 35.45% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL
35.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.20%

Max
18.05%
SNY
8.20%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Exelixis (EXEL) at 40.75% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max
83.12%
EXEL
40.75%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.89%

Max
83.12%
SNY
30.89%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Exelixis (EXEL) and Sanofi (SNY)
MetricEXELSNY
ROE (TTM)44.32%5.72%
ROA (TTM)23.52%5.31%
Net Margin (TTM)35.45%8.20%
Operating Margin (TTM)40.75%30.89%
Gross Margin (TTM)96.26%73.68%

Growth

Revenue Growth

Both Exelixis (EXEL) at 6.98% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Exelixis (EXEL) at 57.95% and Sanofi (SNY) at 39.43% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Exelixis (EXEL) and Sanofi (SNY)
MetricEXELSNY
Revenue Growth (YoY)6.98%5.49%
Revenue Growth (3Y CAGR)12.93%4.82%
EPS Growth (YoY)57.95%39.43%
EPS Growth (3Y CAGR)70.59%6.02%

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max
25.13
Q3
12.13
Median
5.52
EXEL
3.21
Q1
2.47
Min
0.10

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
SNY
1.12
Min
0.10
Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Exelixis (EXEL) at 0.09 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
EXEL
0.09
Q1
0.02
Min
0.00

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.27

Max
1.42
Q3
0.65
SNY
0.27
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Exelixis (EXEL) and Sanofi (SNY)
MetricEXELSNY
Current Ratio (MRQ)3.211.12
Debt / Equity (MRQ)0.090.27
Net Debt / EBITDA-0.710.96

Dividends

Dividend Yield (TTM)

Neither Exelixis (EXEL) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Exelixis (EXEL) pays no dividend (payout 0.00%).

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

119.86%

SNY
119.86%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Exelixis (EXEL) and Sanofi (SNY)
MetricEXELSNY
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%119.86%

Valuation

P/E Ratio (TTM)

Both Exelixis (EXEL) at 20.83 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max
85.34
Q3
43.46
Median
26.69
EXEL
20.83
Q1
13.30
Min
0.07

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.40

Max
85.34
Q3
43.46
Median
26.69
SNY
23.40
Q1
13.30
Min
0.07
Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Exelixis (EXEL) at 6.80 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max
58.18
Q3
25.77
Median
7.30
EXEL
6.80
Q1
3.01
Min
0.01

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.21

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
SNY
2.21
Min
0.01
Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Sanofi (SNY) at 1.38 looks cheap against book in the lower P/B ratio quartile, while Exelixis (EXEL) at 9.28 carries a premium in the upper quartile — a clear price-to-book gap.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max
13.53
EXEL
9.28
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
SNY
1.38
Min
-5.59
Loading chart…
Exelixis (EXEL) vs. Sanofi (SNY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Exelixis (EXEL) and Sanofi (SNY)
MetricEXELSNY
P/E Ratio (TTM)20.8323.40
P/S Ratio (TTM)6.802.21
P/B Ratio (MRQ)9.281.38
Free Cash Flow Yield (TTM)4.47%7.17%